Research programme: anti-infectives - Welichem BiotechAlternative Names: Anti-infectives research programme - Welichem Biotech; Infectious diseases research programme - Welichem Biotech
Latest Information Update: 16 Jul 2016
At a glance
- Originator Welichem Biotech
- Class Small molecules
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Bacterial infections; Mycoses
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Bacterial-infections in Canada
- 16 Jul 2016 No recent reports of development identified for preclinical development in Mycoses in Canada
- 05 Mar 2003 Preclinical trials in Mycoses in Canada (unspecified route)